EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - EyePoint Pharmaceuticals reported a revenue of $24.45 million for the quarter ended March 2025, marking a significant increase of 109.4$0.65, slightly worse than the -$0.55 EPS from the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate by 345.17$5.49 million [1] - The consensus EPS estimate was also -$0.65, indicating no EPS surprise [1] Revenue Breakdown - Royalty income reached$12.69 million, significantly surpassing the three-analyst average estimate of $0.33 million [4] - Product sales, net, amounted to$0.72 million, slightly below the two-analyst average estimate of $0.85 million [4] - Revenue from license and collaboration agreements was$11.05 million, exceeding the average estimate of $6.90 million based on two analysts [4] Stock Performance - EyePoint Pharmaceuticals' shares have returned +51.3% over the past month, outperforming the Zacks S&P 500 composite, which saw a +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]